The largest North American breast cancer prevention trial ever undertaken, the Study of Tamoxifen and Raloxifene (STAR), reached it's goal of enrolling 19,000 women to the trial in June, 2004. Grand Rapids Clinical Oncology Program enrolled 226 women!
Important study results released. Study results continue to confirm effectiveness. UserFiles/File/P2_Press_Release_041910.pdf
UserFiles/File/STAR AACR Press Release 4-19-10-GRCOP PAB.pdf
One STAR participant tells her story: www.mlive.com/news/grand-rapids/index.ssf/2009/07/gr_resident_with_family_histor.html
SELECT closed in June, 2004 exceeding Its accrual goal of 32,000 by 3,534 men. Grand Rapids Clinical Oncology Program enrolled 356 men. We will contunue to provide updates as they are published.